Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -32.46% is 55% above its 5-year average of -72.90%, near the high end of its 5-year range (-203.84%–-13.09%).
47.27% above its 12-month average of -61.56%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.81%.
RETURN ON ASSETS (ROA)
-32.46%
RETURN ON ASSETS (ROA) AVG TTM
-61.56%
RETURN ON ASSETS (ROA) AVG 3Y
-55.11%
RETURN ON ASSETS (ROA) AVG 5Y
-72.90%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+47.27%
CURRENT VS 3Y AVG
+41.10%
CURRENT VS 5Y AVG
+55.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 623 covered companies
CURRENT VS SECTOR MEDIAN
-11.36%
vs the sector median at left
Jade Biosciences, Inc.
Market Cap
$821.00M
Return on Assets (ROA)
-32.46%
TTM Avg
-61.56%
3Y Avg
-55.11%
5Y Avg
-72.90%
Market Cap
$809.02M
Return on Assets (ROA)
-9.67%
TTM Avg
-10.63%
3Y Avg
-19.71%
5Y Avg
-38.52%
Market Cap
$830.70M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$805.59M
Return on Assets (ROA)
10.76%
TTM Avg
17.66%
3Y Avg
20.82%
5Y Avg
23.86%
Market Cap
$838.16M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
Market Cap
$847.73M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$784.35M
Return on Assets (ROA)
-5.26%
TTM Avg
0.19%
3Y Avg
-3.34%
5Y Avg
-3.22%
Market Cap
$785.44M
Return on Assets (ROA)
-8.70%
TTM Avg
6.33%
3Y Avg
-16.09%
5Y Avg
-46.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $821.00M | -32.46% | -61.56% | -55.11% | -72.90% |
| Ardelyx, Inc. (ARDX)vs › | $809.02M | -9.67% | -10.63% | -19.71% | -38.52% |
| Apnimed, Inc. (APMD)vs › | $807.90M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $830.70M | -78.30% | -72.68% | -105.45% | -105.45% |
| InMode Ltd. (INMD)vs › | $805.59M | 10.76% | 17.66% | 20.82% | 23.86% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | -24.96% | -29.43% | -70.30% | -70.30% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $847.73M | -23.15% | -12.59% | -25.36% | -32.38% |
| AdaptHealth Corp. (AHCO)vs › | $784.35M | -5.26% | 0.19% | -3.34% | -3.22% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $785.44M | -8.70% | 6.33% | -16.09% | -46.82% |
| Geron Corporation (GERN)vs › | $769.83M | -13.47% | -22.22% | -41.40% | -40.82% |
ROA
-32.5%
ROE
-34.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -36.43% |
| 2024-12-31 | -86.68% |
| 2023-12-31 | -59.27% |
| 2022-12-31 | -38.07% |
| 2021-12-31 | -13.09% |
| 2020-12-31 | -203.84% |
